Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR | Market Cap | 961.26B -8.5% |
| Revenue (ttm) | 331.19B -0.9% |
| Net Income | 33.11B -41.7% |
| EPS | 39.72 -41.7% |
| Shares Out | 832.98M |
| PE Ratio | 29.05 |
| Forward PE | 25.49 |
| Dividend | 8.00 (0.69%) |
| Ex-Dividend Date | Jul 10, 2026 |
| Volume | 29,778 |
| Open | 1,150.00 |
| Previous Close | 1,154.00 |
| Day's Range | 1,142.55 - 1,161.00 |
| 52-Week Range | 1,080.05 - 1,414.40 |
| Beta | 0.24 |
| Analysts | Hold |
| Price Target | 1,265.77 (+10.55%) |
| Earnings Date | Oct 30, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as ... [Read more]
Financial Performance
In fiscal year 2026, Dr. Reddy's Laboratories's revenue was 335.93 billion, an increase of 3.19% compared to the previous year's 325.54 billion. Earnings were 42.85 billion, a decrease of -24.22%.
Financial StatementsAnalyst Summary
According to 39 analysts, the average rating for 500124 stock is "Hold." The 12-month stock price target is ₹1,266, which is an increase of 10.55% from the latest price.
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such invest...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors a...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investor...
Dr Reddy’s arm Aurigene inks global drug manufacturing deal with pharma giant
Dr Reddy’s subsidiary Aurigene signs long-term manufacturing and supply deal with a global pharma for 20+ products, targeting US, Europe, Canada, and emerging markets.
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Dr. Reddy's Laborat...
Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Co...
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) on behalf of investors concerning the...
Dr. Reddy’s says FDA inspection of UK facility ‘officially closed’
Dr. Reddy’s (RDY) announced that the FDA’s inspection of its West Yorkshire, United Kingdom manufacturing facility is “officially closed.”
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
NEW YORK--(BUSINESS WIRE)---- $RDY #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”...
DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY). The inv...
Laurus Labs surges past Rs 1 lakh crore MCAP & biggies like Dr Reddy’s
Laurus Labs hits Rs 1 lakh crore market cap as shares rally 115% in a year, overtaking Dr Reddy’s and Aurobindo; Divi’s crosses Rs 2.2 lakh crore.
Dr. Reddy's Launches First-to-Market Generic Sugammadex Injection In The U.S
(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY) announced the U.S. launch of its Sugammadex Injection in single-dose vials of 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL), marking the first gen...
Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bridion--Dr. Reddy's Laboratories today announced launch of Sugammadex Injection of Single-Dose Vials, a generic equivalent of Bridion®, i...
Dr Reddy’s registers PD-1 inhibitor for rare head and neck cancer in South Africa
Dr Reddy’s Labs South Africa registers a PD-1 inhibitor for recurrent/metastatic nasopharyngeal carcinoma, aiming to expand access to oncology care.
Dr Reddy’s gets USFDA nod for Rituximab biosimilar
USFDA approves Dr Reddy’s rituximab biosimilar to Rituxan; Fresenius Kabi to exclusively commercialise in the US, expanding Dr Reddy’s biologics portfolio.
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
Investigation focuses on RDY losses after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches and shares fell approximately 9%. NEW YORK, July 31, 2026 /PRNewswire/ ...
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)
RDY shares fell approximately 9% after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches. The investigation focuses on the Company's regulatory statements about se...
RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)
NEW YORK--(BUSINESS WIRE)--RDY shareholders saw Dr. Reddy's Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a ₹2.4 billion provision tied to out-...
Thailand approves Nuzolvence antibiotic for gonorrhoea treatment
Thailand approves Nuzolvence (zoliflodacin), a first-in-class oral gonorrhoea antibiotic, for patients 12+; Dr Reddy’s and GARDP led review amid resistance.
Trump's Tariffs Are Targeting Indian Drugmakers. Americans Could Soon Pay More for Generic Medicines, CEO Warns
Erez Israeli, CEO of Dr. Reddy's Laboratories, said that President Donald Trump's proposed tariffs on imported generic medicines would inevitably translate into higher prices for patients.
Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)
RDY shares fell approximately 9% after Q1 FY27 results showed a 5.66% year-over-year revenue decline and a 68.7% profit decline. The investigation focuses on investor losses tied to the market reactio...
U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO
In this CNBC exclusive, Dr. Reddy's Laboratories CEO Erez Israeli breaks down the company's recent Q1 earnings report. He addresses the temporary halt in Semaglutide production due to an impurity issu...
U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns
U.S. President Donald Trump's plan to impose tariffs on generic drugs will lead to patients in the U.S. paying higher prices, warned the CEO of Indian pharmaceutical company Dr Reddy's. Manufacturing ...
Dr Reddy's Laboratories Ltd (RDY) Shares Surge 3.7% -- What GF Score of 83 Tells Investors
Dr Reddy's Laboratories Ltd (RDY) Shares Surge 3.7% -- What GF Score of 83 Tells Investors